Lanlan Zhou

3.0k citations

101 papers · 1.9k indexed · 1 hit paper · h-index 22

Impact in

Cancer Research top 5%
- Cancer Genomics and Diagnostics
Oncology top 5%
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways

Papers in ⓘ

Molecular Biology 49
- Cell death mechanisms and regulation 14
- Cancer therapeutics and mechanisms 12
- Histone Deacetylase Inhibitors Research 7
- Protein Degradation and Inhibitors 6
Oncology 48
- Cancer-related Molecular Pathways 13
- PARP inhibition in cancer therapy 6
- Cancer Treatment and Pharmacology 5

Co-authors: Wafik S. El‐Deiry (73 shared papers)Joseph J. Drabick (4 shared papers)Cristina I. Truica (4 shared papers)Ming Dao (1 shared paper)Po‐Hsun Huang (1 shared paper)Yuchao Chen (1 shared paper)Peng Li (1 shared paper)Zhangli Peng (1 shared paper)
Journals: Cancer Research (25 papers)Cancer Biology & Therapy (6 papers)Oncotarget (5 papers)Cell Cycle (5 papers)Journal of Clinical Oncology (4 papers)
Partner nations: United States China India

In The Last Decade

Lanlan Zhou

91 papers receiving 1.9k citations

Hit Papers

align trajectories log scale

Acoustic separation of circulating tumor cells 2015 · 635 citations

Peers

Countries citing papers authored by Lanlan Zhou

Since Specialization

Citations

This map shows the geographic impact of Lanlan Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lanlan Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lanlan Zhou more than expected).

Fields of papers citing papers by Lanlan Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lanlan Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lanlan Zhou. The network helps show where Lanlan Zhou may publish in the future.

Co-authors

The 25 scholars most cited alongside Lanlan Zhou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lanlan Zhou Line = papers co-authored together Lanlan Zhou links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 101 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Acoustic separation of circulating tumor cells Proceedings of the National Academy of Sciences ·Peng Li, Zhangming Mao, Zhangli Peng, Lanlan Zhou, Yuchao Chen, Po‐Hsun Huang, Cristina I. Truica, Joseph J. Drabick, Wafik S. El‐Deiry, Ming Dao, Subra Suresh, Tony Jun Huang Hit paper breakdown →	2015	635
2	Targeting the Integrated Stress Response in Cancer Therapy Frontiers in Pharmacology ·Xiaobing Tian, Shengliang Zhang, Lanlan Zhou, Attila A. Seyhan, Liz Hernandez Borrero, Yiqun Zhang, Wafik S. El‐Deiry	2021	101
3	Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53 Cancer Research ·Shengliang Zhang, Lanlan Zhou, Bo Hong, A. Pieter J. van den Heuvel, Varun V. Prabhu, Noel A. Warfel, C. Leah B. Kline, David T. Dicker, Levy Kopelovich, Wafik S. El‐Deiry	2015	92
4	AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing Cell Death Discovery ·İlyas Şahin, Shengliang Zhang, Arunasalam Navaraj, Lanlan Zhou, Don S. Dizon, Howard Safran, Wafik S. El‐Deiry	2020	56
5	Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212 Cell Cycle ·Jessica Wagner, C. Leah B. Kline, Marie D. Ralff, Avital Lev, Amriti R. Lulla, Lanlan Zhou, Gary L. Olson, Bhaskara Rao Nallaganchu, Cyril H. Benes, Joshua E. Allen, Varun V. Prabhu, Martin Stogniew, Wolfgang Oster, Wafik S. El‐Deiry	2017	56
6	Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment Journal of Clinical Investigation ·Jessica Wagner, C. Leah B. Kline, Lanlan Zhou, Kerry S. Campbell, Alexander W. Macfarlane, Anthony J. Olszanski, Kathy Q. Cai, Harvey H. Hensley, Eric A. Ross, Marie D. Ralff, Andrew Zloza, Charles B. Chesson, Jenna H. Newman, Howard L. Kaufman, Joseph Bertino, Mark N. Stein, Wafik S. El‐Deiry	2018	55
7	Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons Current Colorectal Cancer Reports ·Carlyn Tan, Lanlan Zhou, Wafik S. El‐Deiry	2016	53
8	Multispectral Fluorescence Imaging Journal of Nuclear Medicine ·Lanlan Zhou, Wafik S. El‐Deiry	2009	48
9	Evaluation of emission factors for light-duty gasoline vehicles based on chassis dynamometer and tunnel studies in Shanghai, China Atmospheric Environment ·Cheng Huang, Shikang Tao, Shengrong Lou, Qingyao Hu, Hongli Wang, Qian Wang, Li Li, Hongyu Wang, Jiangang Liu, Yifeng Quan, Lanlan Zhou	2017	45
10	Metabolic imaging of tumors using intrinsic and extrinsic fluorescent markers Biosensors and Bioelectronics ·Zhihong Zhang, Hui Li, Qian Liu, Lanlan Zhou, Min Zhang, Qingming Luo, Jerry D. Glickson, Britton Chance, Gang Zheng	2004	43
11	MicroRNA Expression Profiles and MiR-10a Target in Anti-benzo[a] pyrene-7, 8-diol-9, 10-epoxide-transformed Human 16HBE Cells Biomedical and Environmental Sciences ·Yuelan Shen, Yiguo Jiang, Anne R. Greenlee, Lanlan Zhou, Linhua Liu	2009	39
12	The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia Cell Cycle ·Jun Zhang, Lanlan Zhou, Shuai Zhao, David T. Dicker, Wafik S. El‐Deiry	2017	38
13	EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG Neoplasia ·Yiqun Zhang, Lanlan Zhou, Howard Safran, Robyn Borsuk, Rishi Lulla, Nikos Tapinos, Attila A. Seyhan, Wafik S. El‐Deiry	2021	37
14	Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies Cell Cycle ·Varun V. Prabhu, Mala K. Talekar, Amriti R. Lulla, C. Leah B. Kline, Lanlan Zhou, Junior Hall, A. Pieter J. van den Heuvel, David T. Dicker, Jawad Babar, Stephan A. Grupp, Mathew J. Garnett, Ultan McDermott, Cyril H. Benes, Jeffrey J. Pu, David F. Claxton, Nadia Khan, Wolfgang Oster, Joshua E. Allen, Wafik S. El‐Deiry	2017	33
15	Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome Journal of Cancer Research and Clinical Oncology ·Lanlan Zhou, Yanan Liu, Zhenzhen Wen, Shimei Yang, Mingjie Li, Qiuhua Zhu, Shiqiu Qiu, Yanmin Gao, Hong Wang, Yuemei Yuan, Hanling Zhang, Chaolun Chen, Wenbin Zeng, Zebing Guan, Xueyi Pan	2020	32
16	Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms Journal of Experimental & Clinical Cancer Research ·Jessica Wagner, C. Leah B. Kline, Lanlan Zhou, Vladimir Khazak, Wafik S. El‐Deiry	2018	29
17	Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics Frontiers in Pharmacology ·Anna D. Louie, Kelsey E. Huntington, Lindsey Carlsen, Lanlan Zhou, Wafik S. El‐Deiry	2021	29
18	ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer Molecular Cancer Therapeutics ·Isacco Ferrarini, Anna D. Louie, Lanlan Zhou, Wafik S. El‐Deiry	2021	28
19	Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors Cell Cycle ·Hairong Cheng, Bo Hong, Lanlan Zhou, Joshua E. Allen, Guihua Tai, Robin Humphreys, David T. Dicker, Yingqiu Y. Liu, Wafik S. El‐Deiry	2012	28
20	Therapeutic targeting of TRAIL death receptors Biochemical Society Transactions ·Francesca Di Cristofano, Andrew George, Vida Tajiknia, Maryam Ghandali, Laura Jinxuan Wu, Yiqun Zhang, Praveen Srinivasan, Jillian Strandberg, Marina Hahn, Ashley Sanchez Sevilla Uruchurtu, Attila A. Seyhan, Benedito A. Carneiro, Lanlan Zhou, Kelsey E. Huntington, Wafik S. El‐Deiry	2023	25

About Lanlan Zhou

Lanlan Zhou is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Immunology and Cancer Research, having authored 101 papers that have together received 1.9k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (14 papers), Cancer-related Molecular Pathways (13 papers), Cancer therapeutics and mechanisms (12 papers), Histone Deacetylase Inhibitors Research (7 papers), PARP inhibition in cancer therapy (6 papers), Cancer, Hypoxia, and Metabolism (6 papers), Protein Degradation and Inhibitors (6 papers) and Cancer Treatment and Pharmacology (5 papers). The work is most often cited by research in Cancer Research (331 citations), Oncology (543 citations), Biomedical Engineering (673 citations), Molecular Biology (749 citations) and Biotechnology (87 citations). Lanlan Zhou has collaborated with scholars based in United States, China and India. Frequent co-authors include Wafik S. El‐Deiry, Joseph J. Drabick, Cristina I. Truica, Ming Dao, Po‐Hsun Huang, Yuchao Chen, Peng Li, Zhangli Peng, Subra Suresh and Zhangming Mao. Their work appears in journals such as Cancer Research, Cancer Biology & Therapy, Oncotarget, Cell Cycle and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact